Oxford Drug Design successfully completes initial in vivo validation in its potential first-in-class approach against multiple cancer
We are excited to share a significant milestone in Oxford Drug Design’s journey towards revolutionising cancer treatment. Dr. Paul Finn, CSO of Oxford…
